학술논문

Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial
Document Type
Article
Source
In: The Lancet Infectious Diseases. (The Lancet Infectious Diseases, 2024)
Subject
Language
English
ISSN
14744457
14733099